About Us

EASTON PHARMACEUTICALS¬†is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women’s diagnostic products and two generic cancer products. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a company holding Medical Marijuana growing rights in California on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

EASTON PHARMACEUTICALS is committed to providing safe and effective products. Testing protocol is extensive for all products. Third party, multi-centre clinical trials will be completed for all products to validate efficacy statements and to give consumers confidence in the products.

Previous versions of ViorraTM have completed and passed irritation, allergic reaction, oral toxicity and three year stability studies. ViorraTM has completed an Open Label Clinical Pilot Trial to evaluate the safety and efficacy of the product. Pre and post-menopausal women with pre-diagnosed sexual function disorder for the past five years tested ViorraTM. There were no adverse data reported during the study and collectively the subjects reported: Less genital pain during intercourse, more sexual attempts with their partner, increase in vaginal lubrication, higher incidence of orgasm, increased desire to engage in sexual activity and an overall increase in sexual satisfaction. Since these tests were performed, Viorra has been reformulated, which have not undergone any additional clinical trials or testing.